Nasdaq · Healthcare

IMMUCELL CORP /DE/ (ICCC)

As-reported financials and recent SEC filings for IMMUCELL CORP /DE/, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$27.6M

Net income

$-1.0M

Net margin

-3.8%

Diluted EPS

$-0.12

ROE

-3.8%

P/E (TTM)

—

Market cap

—

Debt / equity

0.3×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$27.6M	$26.5M	$17.5M	$18.6M	$19.2M
Gross profit	$11.4M	$7.9M	$3.9M	$7.6M	$8.7M
Operating income	$1.6M	$-1.6M	$-5.7M	$-2.3M	$257,385
Net income	$-1.0M	$-2.2M	$-5.8M	$-2.5M	$-78,292
Diluted EPS	$-0.12	$-0.26	$-0.75	$-0.32	$-0.01

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-22

8-K2026-06-17

8-K2026-06-10

8-K2026-05-14

10-Q2026-05-14

10-K/A2026-05-13

8-K2026-05-08

DEF 14A2026-04-24

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ICCC

Search IMMUCELL CORP /DE/’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.